Notice2024-23597
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 11, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 198 (Friday, October 11, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 198 (Friday, October 11, 2024)]
[Notices]
[Pages 82628-82629]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-23597]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness
Consortium
Notice is hereby given that, on July 11, 2024, pursuant to section
6(a) of the National Cooperative Research and
[[Page 82629]]
Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''),
Biopharmaceutical Manufacturing Preparedness Consortium (``BioMaP-
Consortium'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Arena BioPharma Consulting LLC, Athens, GA;
ReechPharma LLC, Newark, CA; Repligen Corp., Waltham, WA; RexSter
Technologies, Inc., Acton, MA; VJ Technologies, Inc., Bohemia, NY;
Altor Safety LLC, Valley Cottage, NY; Anverra Pharma LLC, Mt. Pleasant,
SC; Arranat Bio MA LLC, Watertown, MA; BioTechnique LLC, York, PA;
Celltheon, Union City, CA; CHO Plus, Inc., South San Francisco, CA;
Cocoon Bioscience S.L., Derio, SPAIN; CONTINUUS Pharmaceuticals, Inc.,
Woburn, MA; Convergence, Oklahoma City, OK; DNA Script, Daly City, CA;
Evonik Corp., Piscataway, NJ; Gerresheimer Glass, Inc., Vineland, NJ;
Innoviva Specialty Therapeutics, Waltham, MA; KBI Biopharma, Durham,
NC; Orexo AB, Morristown, NJ; Persist AI Formulations Corp., West
Sacramento, CA; Phenom Pharmaceuticals LLC, Miami Beach, FL; Shionogi,
Inc., Florham Park, NJ; Solaris Vaccines, Inc., Fort Collins, CO;
Spring Discovery, Inc., San Carlos, CA; Sublime LLC, Ann Arbor, MI,
Watson-Marlow, Inc., Wilmington, MA; Apotex Corp., Weston, FL; Avid
Bioservices, Inc., Tustin, CA; Burrell International Group LLC,
Washington, DC; Dark Wolf Solutions LLC, Herdon, VA; GENEVATIONUS LLC,
Sacramento, CA; Gusmer Enterprises, Inc., Mountainside, NJ; Integrated
Pharma Services, Rockville, MD; Replicate Bioscience, San Diego, CA;
Seqirus, Inc., Holly Springs, NC; Signet Healthcare Management LLC, New
York, NY; Sterigenics Radiation Technologies LLC, Oak Brook, IL; The
Albert B. Sabin Vaccine Institute, Inc., Washington, DC; Virica
Biotech, Ottawa, CANADA; Agile GxP Technologies, Providence, RI; Allied
Technologies and Consulting LLC, Frederick, MD; Global Key Solutions
Corp., Dalton, PA; Industrial Info Resources, Inc., Sugar Land, TX;
Prince Sterilization Services LLC, Pine Brook, NJ; Curia Global, Inc.,
Albany, NY; Donaldson Company, Inc., Bloomington, MN; GCM Pharma, St.
Louis, MO; Photosynthetic B.V., Amsterdam, NETHERLANDS; Revagenix,
Inc., San Francisco, CA; Agno Pharmaceuticals LLC, Bethlehem, PA;
BioAnalysis LLC, Philadelphia, PA; Cornerstone Government Affairs,
Inc., Washington, DC; Cytophage Technologies, Inc., Winnipeg, CANADA;
Humanetics Corp., Edina, MN; NorthX Biologics AB, Matfors, SWEDEN;
Novavax, Inc., Gaithersburg, MD; Quantiscope PBC, Salt Lake City, UT;
Stoic Bio, Inc., San Diego, CA; and Sunflower Therapeutics PBC,
Hingham, MA, have been added as parties to this venture.
Also, Quantum Four Labs LLC, Arcadia, CA, has withdrawn as party to
this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and the BioMaP-Consortium intends to
file additional written notifications disclosing all changes in
membership.
On January 5, 2024, the BioMaP- Consortium filed its original
notification pursuant to section 6(a) of the Act. The Department of
Justice published a notice in the Federal Register pursuant to section
6(b) of the Act on April 16, 2024 (89 FR 26923).
The last notification was filed with the Department on April 12,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on June 21, 2024 (89 FR 52097).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-23597 Filed 10-10-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on October 11, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.